Nishi Shakya Selected Research

N- palmitoyl- S- (2,3- bis(palmitoyloxy)propyl)cysteinyl- seryl- lysyl- lysyl- lysyl- lysine

7/2012	Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis.
10/2011	Effect of Pam3Cys induced protection on the therapeutic efficacy of miltefosine against experimental visceral leishmaniasis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nishi Shakya Research Topics

Disease

8	Visceral Leishmaniasis (Kala Azar) 08/2012 - 07/2010
4	Leishmaniasis 07/2012 - 05/2008
1	Body Weight (Weight, Body) 07/2011
1	Infections 05/2008

Drug/Important Bio-Agent (IBA)

7	miltefosine (Impavido)IBA 08/2012 - 07/2010
2	LipopeptidesIBA 07/2012 - 10/2011
2	N- palmitoyl- S- (2,3- bis(palmitoyloxy)propyl)cysteinyl- seryl- lysyl- lysyl- lysyl- lysineIBA 07/2012 - 10/2011
2	kutkinIBA 08/2011 - 02/2011
2	Immunologic Factors (Immunomodulators)IBA 08/2011 - 07/2011
2	CPG-oligonucleotideIBA 07/2011 - 07/2010
2	OligodeoxyribonucleotidesIBA 07/2011 - 07/2010
1	TuftsinIBA 08/2012
1	Ketoconazole (Nizoral)FDA LinkGeneric 08/2011
1	ODN2006IBA 07/2011
1	Paromomycin (Paromomycin Sulfate)FDA LinkGeneric 02/2011
1	sephadexIBA 05/2008
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 05/2008

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 04/2011
1	Therapeutics 02/2011
1	Duration of Therapy 02/2011